FIELD: organic chemistry, medicine.
SUBSTANCE: invention relates to novel compounds of the general formula (I): 
wherein R1 represents hydrogen atom or linear or branched (C1-C4)-alkyl group; R2 represents hydrogen atom or linear or branched (C1-C4)-alkyl group; R3 represents phenyl, thienyl or furyl group that are substituted optionally with one or more linear or branched (C1-C4)-alkyl group, linear or branched (C1-C4)-alkoxy-group or halogen atom; R4 and R5 represent independently of one another hydrogen atom, (C3-C6)-cycloalkyl group, linear or branched (C1-C4)-alkyl group comprising optionally amino-group or amino-group substituted with one or two linear or branched (C1-C4)-alkyl groups, hydroxy-group, carboxy-group or alkoxy-group substituted with linear or branched (C1-C4)-alkyl group; or R4 represents hydrogen atom or linear or branched (C1-C4)-alkyl group or benzyl group; R5 represents hydrogen atom, group -SO2OH or formyl group, or R4 and R5 in common with nitrogen atom form group of the general formula (a): 
wherein R7 and R8 represent independently one another hydrogen atom, linear or branched (C1-C4)-alkyl group; R6 represents phenyl, benzyl, thienyl or furyl group that are substituted optionally with methylenedioxy-group or one or more linear or branched (C1-C4)-alkyl group, linear or branched (C1-C4)-alkoxy-group or halogen atom; X represents group -NH or oxygen atom; Z represents oxygen atom, sulfur atom, group -CH2, group -NH or group -NR11 wherein R11 represents hydrogen atom, linear or branched (C1-C4)-alkyl group, group -SO2OH, linear or branched (C1-C4)-acyl group; n = 0, 1 or 2; m = 1, 2 or 3; o = 1, 2 or 3; p = 0 or 1; r = 0 or 1, and their salts and solvates. Also, invention relates to a method for synthesis of compounds of the general formula (I), to a pharmaceutical composition, its using and to compounds of the general formulas (I''), (II''), (III''), (IV''), (V''), (VI''), (VII''), (VIII'') and (XIII'') given in the invention description. Invention provides synthesis of novel biologically active compounds that are ligands of adenosine A3 receptors but as antagonists preferably.
EFFECT: valuable biological properties of compounds.
20 cl, 1 tbl, 40 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF AMINOQUINOLINE AND AMINOPYRIDINE AND THEIR USING AS ADENOSINE LIGANDS A | 2002 |
|
RU2278112C2 |
| TRIAZOLO[1,5-a]QUINOLINES AS LIGANDS OF ADENOSINE A3 RECEPTOR | 2008 |
|
RU2489432C2 |
| METHOD OF RESIDUAL LIPOPROTEINS PRODUCING INHIBITION | 2004 |
|
RU2330682C2 |
| PYRAZOLAMINOPIRIMIDINE DERIVATIVES AS LEUCINE-REPEATING KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON DISEASE | 2013 |
|
RU2637948C2 |
| BRANCHED ALKYLAMINO DERIVATIVES OF THIAZOLE OR THEIR POTENTIAL STEREOISOMERS OR THEIR ADDITIVE SALTS WITH MINERAL OR ORGANIC ACID, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION HAVING ACTIVITY IN RESPECT WITH FACTOR OF RELEASING OF CORTICOTROPIC HORMONE AND ALKYLAMINO DERIVATIVES OF THIAZOLE AS INTERMEDIATE COMPOUNDS | 1993 |
|
RU2102389C1 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | 2011 |
|
RU2623427C2 |
| NOVEL DERIVATIVES OF ARYLIMIDAZOLE, THEIR PREPARATIONS AND THEIR THERAPEUTIC USES | 2003 |
|
RU2323216C2 |
| NOVEL COMPOUNDS POSSESSING ANTI-INFLAMMATORY ACTIVITY AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | 2001 |
|
RU2288225C2 |
| 3-CYANOQUINOLIMES AS INHIBITORS OF EGF-R AND HER2 KINASES | 2002 |
|
RU2309150C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
